Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy

Mantle cell lymphoma (MCL) is an incurable intermediate-grade lymphoma representing 5–6% of non-Hodgkin’s lymphomas diagnosed in the United States. The introduction of inhibitors of Bruton’s tyrosine kinase (BTK) into targeted therapy for MCL has significantly improved outcomes in patients with rela...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: Girard, Jennifer, Reneau, John, Devata, Sumana, Wilcox, Ryan A, Kaminski, Mark S, Mercer, Jessica, Carty, Shannon, Phillips, Tycel J
Format: Artigo
Language:Inglês
Published: Dove 2019
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777435/
https://ncbi.nlm.nih.gov/pubmed/31686856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S155778
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items